secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056925
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus Therapeutics Q1 net loss $13.7M; cash $377M funds into 2H 2027
-----------------------------------------------------------------------

- Net loss $13.7M ($0.54/share) vs $7.1M ($8.10/share) in Q1 2023.
- Cash, equivalents, short-term investments $377M post $230M Jan 2024 PIPE.
- Phase 2 MaGic trial in gMG ongoing; top-line results expected 2H 2025.
- MMN Phase 2 trial to start Q2 2024; CIDP Phase 2 trial in 2H 2024.
- R&D expense $13.1M (incl. $0.8M SBC); G&A $5.6M (incl. $1.2M SBC).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000095017024056925/0000950170-24-056925-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000095017024056925/dnth-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056925

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer